REDWOOD CITY, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the launch of its ...

Researchers show that polymerase theta can efficiently convert RNA sequences back into DNA, a feat more common in viruses than eukaryotic cells. Editor's Note: Thomas Jefferson University issued the ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Surface model of SpCas9–reverse transcriptase–pegRNA–target DNA complex. The prime editor, composed of a SpCas9 and a reverse transcriptase, reverse transcribes template sequence in pegRNA, resulting ...

The Aicardi–Goutières syndrome is a genetic encephalopathy that is associated with childhood illness and death. The syndrome is hypothesized to be due to misidentification of self-derived nucleic ...

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

A newly revealed drug-binding site on human immunodeficiency virus reverse transcriptase could lead to a new class of HIV medications. Structures of drug complexes of HIV reverse transcriptase have ...

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it ...